Cargando…

Targeting mutant p53 for cancer therapy

Detalles Bibliográficos
Autores principales:	Oren, Moshe, Tal, Perry, Rotter, Varda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931821/ https://www.ncbi.nlm.nih.gov/pubmed/27347904 http://dx.doi.org/10.18632/aging.100992

Ejemplares similares

Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides
por: Tal, Perry, et al.
Publicado: (2016)

Correction: Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides
por: Tal, Perry, et al.
Publicado: (2019)

Pseudo-mutant P53 is a unique phenotype of DNMT3A-mutated pre-leukemia
por: Tuval, Amos, et al.
Publicado: (2022)

Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation
por: Aylon, Yael, et al.
Publicado: (2009)

Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis
por: Stein, Yan, et al.
Publicado: (2019)

Mutant p53—a potential player in shaping the tumor–stroma crosstalk
por: Stein, Yan, et al.
Publicado: (2019)

Mutant p53 Attenuates the Anti-Tumorigenic Activity of Fibroblasts-Secreted Interferon Beta
por: Madar, Shalom, et al.
Publicado: (2013)

Selective targeting of p53 gain-of-function mutants in cancer
por: Padmanabhan, Achuth
Publicado: (2018)

Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers
por: Solomon, Hilla, et al.
Publicado: (2018)

Drugging p53 in cancer: one protein, many targets
por: Hassin, Ori, et al.
Publicado: (2022)

p53 on the crossroad between regeneration and cancer
por: Charni, Meital, et al.
Publicado: (2017)

Targeting Oncogenic Mutant p53 for Cancer Therapy
por: Parrales, Alejandro, et al.
Publicado: (2015)

Mutant p53 in Cancer Progression and Targeted Therapies
por: Zhu, Gaoyang, et al.
Publicado: (2020)

Targeting mutant p53 stabilization for cancer therapy
por: Wang, Jiajian, et al.
Publicado: (2023)

Chromatin dysregulation by mutant p53
por: Pfister, Neil T., et al.
Publicado: (2016)

Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells
por: Grespi, Francesca, et al.
Publicado: (2016)

Flipping the “switch” on mutant p53 by zinc metallochaperones: how a brief pulse of zinc can reactivate mutant p53 to kill cancer
por: Yu, Xin, et al.
Publicado: (2019)

p53 balances between tissue hierarchy and anarchy
por: Koifman, Gabriela, et al.
Publicado: (2019)

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells
por: Sarig, Rachel, et al.
Publicado: (2010)

Corrigendum to ‘p53 balances between tissue hierarchy and anarchy’
por: Koifman, Gabriela, et al.
Publicado: (2019)

Mutant p53 and sIL-1Ra
por: Bossi, Gianluca
Publicado: (2015)

p53 and the Viral Connection: Back into the Future ‡
por: Aloni-Grinstein, Ronit, et al.
Publicado: (2018)

Targeting mutant p53 for cancer therapy: direct and indirect strategies
por: Hu, Jiahao, et al.
Publicado: (2021)

The SLC25A1-p53 mutant crosstalk
por: Albanese, Chris, et al.
Publicado: (2015)

Small ceramide tames big p53 mutant beast
por: Hill, Ronald A., et al.
Publicado: (2020)

p53: not just a tumor suppressor
por: Oren, Moshe
Publicado: (2019)

Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53
por: Vikhanskaya, Faina, et al.
Publicado: (2007)

Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy
por: Lonetto, Giuseppe, et al.
Publicado: (2018)

Targeting mutant p53 in cancer: the latest insights
por: Di Agostino, Silvia, et al.
Publicado: (2019)

How mutant p53 empowers Foxh1 fostering leukaemogenesis?
por: Amelio, Ivano
Publicado: (2019)

Mutant p53 in cancer therapy—the barrier or the path
por: Zhou, Xiang, et al.
Publicado: (2018)

Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate
por: Shalgi, Reut, et al.
Publicado: (2009)

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
por: Kong, Li Ren, et al.
Publicado: (2020)

Editor's Note on ‘Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53’
Publicado: (2023)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Liver and Steroid Hormones—Can a Touch of p53 Make a Difference?
por: Charni-Natan, Meital, et al.
Publicado: (2019)

p53, a novel regulator of lipid metabolism pathways
por: Goldstein, Ido, et al.
Publicado: (2012)

Gain-of-function mutant p53 in cancer progression and therapy
por: Zhang, Cen, et al.
Publicado: (2020)

The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
por: Kadosh, Eliran, et al.
Publicado: (2020)

Mutant p53 in colon cancer
por: Nakayama, Mizuho, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cdtisivn5vm561rnphp48s5q9u